XML 32 R21.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2

Revenues (Tables)

3 Months Ended

Mar. 31, 2024

Revenues [Abstract]

Schedule of net product revenues by product

The Company’s net revenues consisted of the following for the three months ended March 31, 2024 and 2023:

			Three months ended March 31,
			2024						2023
Products:
Kristalose			$	3,195,609					$	4,315,128
Sancuso			1,827,769						1,886,793
Vibativ			1,605,489						1,848,187
Caldolor			1,470,699						935,043
Acetadote			80,203						169,856
Vaprisol			8,662						16,008
Omeclamox-Pak			(1,615)						(2,518)
RediTrex			35,556						(141,045)
Other revenue			275,329						197,186
Total net revenues			$	8,497,701					$	9,224,638

X

- References

No definition available.

+ Details

Name:	us-gaap_RevenuesAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

+ Details

Name:	us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration